Bronchoalveolar carcinoma: current treatment and future trends.
Bronchoalveolar carcinoma (BAC) is a subtype of non-small-cell lung cancer (NSCLC) with unique clinical and pathologic characteristics. The most recent classification system defines BAC as a primary lung cancer that tends to be peripheral and grow in a lepedic fashion along the alveolar septae without parenchymal invasion. Most of the clinical information on BAC comes from retrospective institutional reviews; however, recent studies have focused more specifically on BAC. In particular, clinical trials of molecular-targeted anticancer therapies against the epidermal growth factor receptor have led to a deeper understanding of the distinct features of this cancer and suggest that BAC may require a therapeutic paradigm different from that of other NSCLCs.
Laskin
Janessa J
JJ
University of British Columbia, Division of Medical Oncology, BC Cancer Agency, Vancouver, Canada. jlaskin@bccancer.bc.ca
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000453:epidemiology / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D011379:Prognosis
D000970:Antineoplastic Agents